Huseni, Mahrukh A.
Genentech
3 papers on CoChatORCID 0000-0001-8166-3401
Most cited papers
- Verified
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine
Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers
Cited by 1,260
- Verified
Peripheral T cell expansion predicts tumour infiltration and clinical response
Wu, T. D., Madireddi, S., de Almeida, P. E., Banchereau, R., Chen, Y.-J. J., Chitre, A. S., Chiang, E. Y., Iftikhar, H., O’Gorman, W. E., Au-Yeung, A., et al. (2020) · Nature
Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology
Cited by 770
- Verified
P3.02c-046 Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC
Rudin, C., Cervantes, A., Dowlati, A., Besse, B., Ma, B., Costa, D., Schmid, P., Heist, R., Villaflor, V., Sarkar, I., et al. (2017) · Journal of Thoracic Oncology
Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers
Cited by 14
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free